PRESS RELEASE published on 02/27/2024 at 16:01, 1 year 9 months ago Original-Research: Valneva (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research GmbH updates Valneva SE research report, reiterating Buy recommendation with a target price of €8.60 based on strong FY/23 product revenue recovery and positive outlook for travel vaccines and future prospects Buy Recommendation Research Update Target Price Valneva SE Product Revenue
BRIEF published on 02/27/2024 at 16:01, 1 year 9 months ago First Berlin updates its recommendation on Valneva with an adjusted price target First Berlin Equity Research Purchase Recommendation Valneva Simon Scholes Course Objective
PRESS RELEASE published on 10/12/2023 at 10:11, 2 years 1 month ago Original-Research: Valneva (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE published on 05/22/2023 at 13:41, 2 years 6 months ago Original-Research: Valneva (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE published on 04/04/2023 at 15:46, 2 years 8 months ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
Published on 12/05/2025 at 02:35, 5 hours 12 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 47 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 42 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 47 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 46 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 16 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 56 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 21 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 31 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:00, 13 hours 47 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 2 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 14 hours 2 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago Declaration of voting rights at the end of November 2025
